In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference.

Dr. Xiuning Le reports updated results of BAY 292708, and Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study, both of which evaluate the efficacy of therapies for patients with HER2-Mutant NSCLC. Dr. Fiona Hegi-Johnson adds her perspective as a discussant of the POLESTAR trial evaluating EGFR therapy after chemoradiation in stage III unresectable NSCLC.

Guests:

Dr. Fiona Hegi-Johnson
Radiation Oncologist at the Peter MacCallum Cancer Centre
Senior Research Fellow at the University of Melbourne

Dr. Xiuning Le, M.D., Ph.D.
Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology
University of Texas M.D. Anderson Cancer Center

Dr. Gerrina Ruiter, M.D., Ph.D.
Pulmonologist Specialized in Thoracic Oncology at the Netherlands Cancer Institute
Amsterdam, The Netherlands